Caristo Diagnostics is a technology company.
Caristo Diagnostics has raised $16.0M across 1 funding round.
Caristo Diagnostics has raised $16.0M in total across 1 funding round.
Caristo Diagnostics is a UK-based medical technology company specializing in AI-powered cardiovascular diagnostics, founded as a spin-out from the University of Oxford.[2][3][4] It develops CaRi-Heart®, an AI platform that analyzes routine coronary CT angiography (CCTA) scans to detect hidden coronary inflammation and plaque, enabling early risk prediction for heart attacks and personalized treatment.[1][2][5][6] Serving clinicians, hospitals, and pharmaceutical companies, Caristo addresses the global rise in cardiovascular disease by improving early diagnosis where traditional tests fall short, with strong growth including over 2x clinical adoption increase in 2024 among clients like the NHS, HCA UK, and Mayo Clinic UK, plus its first U.S. office launch.[1]
The company solves the problem of invisible coronary inflammation—known for over 50 years as a heart attack cause but previously undetectable in standard scans—by extracting this data to guide proactive interventions, reducing healthcare burdens.[2] Momentum is accelerating with new EU/UK clients, partnerships like serving as imaging core lab for NewAmsterdam Pharma's REMBRANDT trial across eight countries, and upcoming products for stroke and diabetes risk prediction.[1][2][3]
Caristo Diagnostics was founded in 2018 by cardiologists at the University of Oxford, building on a decade of prior scientific research and technical development to revolutionize heart disease diagnosis and treatment.[2] The idea emerged from the recognition that coronary inflammation drives heart attacks, yet routine cardiac tests couldn't visualize it—leading to the creation of CaRi-Heart®, which unlocks this insight from existing CT scans.[2]
Early traction included securing CE mark under the stringent MDR process in February 2021, enabling commercial availability in Europe, the UK, and Australia.[2] Pivotal moments feature rapid 2024 expansion with doubled clinical adoption, strategic NHS and private hospital partnerships, and global pharma trials, alongside opening a U.S. office in Stamford, Connecticut, under CEO Frank Cheng.[1][3]
Caristo rides the wave of AI-driven precision medicine in cardiovascular health, where multimodal AI analyzes routine imaging to preempt heart disease amid rising global incidence of attacks and strokes.[1][6] Timing is ideal as coronary CT adoption surges, yet inflammation detection lags—Caristo bridges this with non-invasive, routine-scan analysis, aligning with preventive care shifts post-COVID and aging populations.[1][2]
Market forces favor it: pharma demand for endpoint biomarkers in trials (e.g., REMBRANDT), healthcare systems seeking cost-effective early intervention, and regulatory nods like MDR CE mark validate scalability.[1][3] It influences the ecosystem by standardizing inflammation metrics, empowering clinicians worldwide, and partnering with innovators like Dr. Eric Topol on AI heart prevention, potentially reshaping trial designs and population screening.[3][6]
Caristo is poised for U.S. FDA clearance and deeper pharma integrations, expanding CaRi-Heart® into stroke/diabetes prediction amid booming demand for AI cardiac tools.[1][2][3] Trends like AI imaging standardization and value-based care will propel growth, with its Oxford-proven tech influencing global guidelines. As cardiovascular burdens escalate, Caristo's inflammation insights could save lives at scale, cementing its lead from 2024's momentum into a preventive diagnostics powerhouse.[1]
Caristo Diagnostics has raised $16.0M in total across 1 funding round.
Caristo Diagnostics's investors include Business Growth Fund, Optum Ventures.
Caristo Diagnostics has raised $16.0M across 1 funding round. Most recently, it raised $16.0M Series A in April 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2023 | $16.0M Series A | Business Growth Fund, Optum Ventures |